Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORAGER-1 LOXO-435 in FGFR3-altered advanced solid tumors including urothelial cancer
jRCT2031230098Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of vepugratinib, pembrolizumab and enfortumab vedotin in transitional cell carcinoma (TCC), bladder cancer, ureteral cancer and 1 more (8 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of participants with dose-limiting toxicities, Overall response rate and 1 more. Started Jul 2023; status: recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancerureteral cancerNonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031230098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230098.